An integrated analysis of Sacituzumab govitecan in relapsed or refractory metastatic triplenegative breast cancer: Erratum

Key Points

• Sacituzumab govitecan shows promise in improving outcomes for relapsed metastatic triple-negative breast cancer patients.
• The study found a significant response rate of 30% among those treated with this novel agent.
• Integrated analysis focused on biomarkers associated with treatment efficacy in a challenging cancer type.
• These findings suggest further exploration of sacituzumab govitecan is warranted in clinical settings.